🇺🇸 FDA
Patent

US 10544232

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 10544232 (Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Jan 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K39/3955, A61P